Maria Planck

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1386150/publications.pdf

Version: 2024-02-01

44	1,022	393982	454577
papers	citations	19 h-index	30 g-index

44	44	44	1729
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Epigenomeâ€wide threeâ€way interaction study identifies a complex pattern between TRIM27, KIAA0226, and smoking associated with overall survival of earlyâ€stage NSCLC. Molecular Oncology, 2022, 16, 717-731.	2.1	4
2	Feasibility of EBUS-TBNA for histopathological and molecular diagnostics of NSCLCâ€"A retrospective single-center experience. PLoS ONE, 2022, 17, e0263342.	1.1	3
3	PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations. International Journal of Molecular Sciences, 2022, 23, 4517.	1.8	7
4	A gene expressionâ€based single sample predictor of lung adenocarcinoma molecular subtype and prognosis. International Journal of Cancer, 2021, 148, 238-251.	2.3	10
5	PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature. Acta Cytologica, 2021, 65, 501-509.	0.7	9
6	Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. Nature Cancer, 2021, 2, 1224-1242.	5.7	37
7	Performance of gene expressionâ€"based single sample predictors for assessment of clinicopathological subgroups and molecular subtypes in cancers: a case comparison study in non-small cell lung cancer. Briefings in Bioinformatics, 2020, 21, 729-740.	3.2	17
8	Analysis of human papillomaviruses and human polyomaviruses in lung cancer from Swedish never-smokers. Acta OncolÃ³gica, 2020, 59, 28-32.	0.8	4
9	Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers. Archives of Pathology and Laboratory Medicine, 2020, 144, 1075-1085.	1.2	38
10	Association of coronary calcium score with endothelial dysfunction and arterial stiffness. Atherosclerosis, 2020, 313, 70-75.	0.4	10
11	Clinical Utility of Targeted Sequencing in Lung Cancer: Experience From an Autonomous Swedish Health Care Center. JTO Clinical and Research Reports, 2020, 1, 100013.	0.6	4
12	Methylation Patterns and Chromatin Accessibility in Neuroendocrine Lung Cancer. Cancers, 2020, 12, 2003.	1.7	5
13	Epigeneticâ€"smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among earlyâ€stage NSCLC patients. Molecular Oncology, 2020, 14, 2759-2774.	2.1	13
14	Comprehensive analysis of RNA binding motif protein 3 (RBM3) in nonâ€small cell lung cancer. Cancer Medicine, 2020, 9, 5609-5619.	1.3	10
15	Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects. Chest, 2020, 158, 808-819.	0.4	26
16	Epigenome-wide geneâ€"age interaction analysis reveals reversed effects of PRODH DNA methylation on survival between young and elderly early-stage NSCLC patients. Aging, 2020, 12, 10642-10662.	1.4	8
17	EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC. Epigenetics, 2019, 14, 118-129.	1.3	28
18	Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence. Acta OncolÃ³gica, 2019, 58, 1079-1086.	0.8	18

#	Article	IF	Citations
19	A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer. Scientific Reports, 2019, 9, 5207.	1.6	17
20	SIPA1L3 methylation modifies the benefit of smoking cessation on lung adenocarcinoma survival: an epigenomicâ€“smoking interaction analysis. Molecular Oncology, 2019, 13, 1235-1248.	2.1	19
21	Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer. Scientific Reports, 2019, 9, 1319.	1.6	11
22	Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases. Human Pathology, 2019, 84, 221-230.	1.1	39
23	Trans-omics biomarker model improves prognostic prediction accuracy for early-stage lung adenocarcinoma. Aging, 2019, 11, 6312-6335.	1.4	13
24	A multiâ€omic study reveals BTG2 as a reliable prognostic marker for earlyâ€stage nonâ€small cell lung cancer. Molecular Oncology, 2018, 12, 913-924.	2.1	31
25	Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC. Clinical Epigenetics, 2018, 10, 41.	1.8	12
26	Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases. American Journal of Clinical Pathology, 2018, 150, 533-544.	0.4	27
27	DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Nonâ€“Small Cell Lung Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1527-1535.	1.1	10
28	Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification. Journal of Thoracic Oncology, 2017, 12, 1257-1267.	0.5	43
29	Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer. Oncotarget, 2017, 8, 34796-34810.	0.8	45
30	CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma. PLoS ONE, 2017, 12, e0186284.	1.1	26
31	Myc-induced glutaminolysis bypasses HIF-driven glycolysis in hypoxic small cell lung carcinoma cells. Oncotarget, 2017, 8, 48983-48995.	0.8	19
32	The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs. Journal of Thoracic Oncology, 2016, 11, 862-872.	0.5	70
33	Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. Oncotarget, 2015, 6, 22028-22037.	0.8	61
34	Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome. Clinical Cancer Research, 2014, 20, 6127-6140.	3.2	91
35	Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History. Clinical Cancer Research, 2014, 20, 4912-4924.	3.2	24
36	Detecting EGFR alterations in clinical specimensâ€”pitfalls and necessities. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 755-764.	1.4	7

#	Article	IF	Citations
37	Immunohistochemistry in the Differential Diagnostics of Primary Lung Cancer. American Journal of Clinical Pathology, 2013, 140, 37-46.	0.4	56
38	Identification of Transcriptional Subgroups in EGFR-Mutated and EGFR/KRAS Wild-Type Lung Adenocarcinoma Reveals Gene Signatures Associated with Patient Outcome. Clinical Cancer Research, 2013, 19, 5116-5126.	3.2	21
39	Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. International Journal of Cancer, 2013, 132, 2020-2031.	2.3	32
40	Histological specificity of alterations and expression of KIT and KITLG in nonâ€small cell lung carcinoma. Genes Chromosomes and Cancer, 2013, 52, 1088-1096.	1.5	17
41	Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status. PLoS ONE, 2013, 8, e78614.	1.1	23
42	Relation between smoking history and gene expression profiles in lung adenocarcinomas. BMC Medical Genomics, 2012, 5, 22.	0.7	41
43	Increased cancer risk in offspring of women with colorectal carcinoma. Cancer, 2000, 89, 741-749.	2.0	15
44	Increased cancer risk in offspring of women with colorectal carcinoma. Cancer, 2000, 89, 741-749.	2.0	1